10-K: Intuitive Surgical Reports Robust 2025 Growth, Driven by da Vinci 5 and Ion Expansion

Intuitive Surgical achieved significant revenue and procedure growth in 2025, fueled by strong adoption of its da Vinci surgical systems, particularly the new da Vinci 5, and expanding use of the Ion endoluminal system.

Summary

• Total revenue increased by 21% to $10.1 billion for the year ended December 31, 2025, compared to $8.4 billion in 2024.
• Approximately 3,153,000 da Vinci procedures were performed in 2025, an 18% increase from 2,683,000 in 2024.
• Ion procedures surged by 51% to approximately 144,100 in 2025, up from 95,500 in 2024.
• Instruments and accessories revenue grew 19% to $6.02 billion, while systems revenue increased 26% to $2.47 billion.
• 1,721 da Vinci surgical systems were placed in 2025, a 13% increase, including 870 da Vinci 5 systems.
• The da Vinci installed base reached approximately 11,106 systems, a 12% increase from 2024.
• Operating income rose 25% to $2.95 billion in 2025, compared to $2.35 billion in 2024.
• The company repurchased 4.8 million shares of common stock for $2.30 billion in 2025.
• Cash, cash equivalents, and investments totaled $9.03 billion as of December 31, 2025.

Sentiment

Score: 8

Explanation: StockSavvy.ai views this as a strong performance, with robust growth across key metrics and successful new product introductions, despite facing some macroeconomic and competitive headwinds.

Positives

• Strong overall revenue growth of 21% year-over-year, indicating robust market demand for products and services.
• Significant increase in da Vinci procedures (18%) and Ion procedures (51%), demonstrating expanding clinical adoption and utilization.
• Successful launch and strong initial placements of the fifth-generation da Vinci 5 surgical system, with 870 units placed in 2025.
• Expansion of the da Vinci installed base by 12% to over 11,000 systems globally, suggesting continued market penetration.
• Increased average selling price (ASP) for da Vinci surgical systems to approximately $1.60 million, driven by favorable product mix including da Vinci 5 sales.
• Regulatory clearances for da Vinci 5 in Japan, South Korea, and Europe, and expanded indications for da Vinci SP in the U.S. and Taiwan, opening new market opportunities.
• FDA clearance for Ion endoluminal system software advancements, integrating AI for improved navigation and lung biopsies.
• Continued investment in research and development, with expenses increasing by 15%, signaling ongoing innovation.
• Active stock repurchase program, with $2.30 billion in repurchases during 2025, returning value to shareholders.
• Strong cash position with $9.03 billion in cash, cash equivalents, and investments, providing financial flexibility.

Negatives

• Ion system placements decreased by 28% in 2025 (195 systems) compared to 2024 (271 systems), primarily in the U.S. as customers shift focus from capacity to utilization.
• Gross profit margin decreased to 66.0% in 2025 from 67.5% in 2024, primarily due to new tariffs, increased fixed overhead costs, and higher costs associated with the da Vinci 5 system.
• U.S. da Vinci bariatric procedures declined in the high-single digits in 2025, attributed to the availability and effectiveness of weight loss drugs.
• Increased competition in China from domestic robotic-assisted surgical system manufacturers and a government anti-corruption campaign have impacted system placements and pricing pressure.
• Tariffs and other trade measures increased cost of revenues by approximately $63.0 million in 2025, with expectations for further increases in 2026.
• Elongated regulatory approval timelines in the U.S. and Europe are anticipated for new products and indications.

Risks

• Highly competitive commercial landscape with existing open surgery, conventional MIS, drug therapies, radiation treatment, and emerging diagnostic/interventional approaches.
• Competition from other robotic-assisted medical procedure companies (e.g., Johnson & Johnson, Medtronic plc, CMR Surgical Ltd., Shanghai Microport Medbot (Group) Co., Ltd.) and industrial robotics companies.
• Macroeconomic conditions (inflation, elevated interest rates, geopolitical conflicts, supply chain disruptions) could adversely impact customer spending, costs, and demand.
• Reliance on soleand single-sourced suppliers for critical components, posing risks of supply disruption and increased costs.
• Potential manufacturing problems or delays, including production yields, quality control, component shortages, and compliance with regulations.
• Litigation risks, including product liability claims, patent infringement, and antitrust claims, which can result in substantial damages or injunctive relief.
• Information technology system failures, cyberattacks, or deficiencies in cybersecurity could harm business operations, customer relations, and lead to data breaches or product functionality issues.
• Failure to achieve and maintain customer acceptance of robotic-assisted medical procedures, especially if alternative treatments become more effective or less expensive.
• Inability of hospitals to obtain sufficient coverage and reimbursement for procedures using products, or government-imposed limitations on charges.
• Product defects or performance problems could lead to recalls, reputational damage, and increased costs.
• Risks associated with international operations, including differing intellectual property laws, regulatory requirements, tariffs, trade barriers, and foreign currency fluctuations.
• Evolving laws and regulations regarding data privacy, data protection, and artificial intelligence, which could lead to significant liability and compliance costs.
• Disruptions at government agencies (e.g., FDA, NMPA, EU notified bodies) could delay product clearances, approvals, or certifications.
• Public health crises or epidemic diseases could divert medical resources, cause staffing shortages, and reduce demand for elective procedures.
• Failure to successfully manage collaborations, joint ventures (e.g., with Fosun Pharma), or acquisitions could prevent realization of expected benefits.
• Exposure to credit risk and fluctuations in the market value of investments, particularly with lease financing arrangements and early-stage company investments.
• Changes in tax laws or exposure to additional tax liabilities, including those from the OECD's Pillar Two solution, could adversely affect financial results.
• Risks associated with real estate construction and development for new facilities, including delays, cost overruns, and regulatory compliance.
• Climate change, natural disasters, or other events beyond control could disrupt business and supply chains.
• Consolidation in the healthcare industry could lead to pricing pressures and reduced demand.
• Uncertainty in estimates, judgments, and accounting methods could cause reported results to vary.

Future Outlook

The company expects research and development expenses and depreciation expense to continue to increase in 2026 due to broader product development initiatives and expanded manufacturing capacity. Cost of revenues driven by tariffs and other trade measures is also expected to increase in 2026. Long-term, the company anticipates OUS procedures and revenue will constitute a greater portion of its business. Future da Vinci system placements will be influenced by supply chain risks, economic and geopolitical factors, hospital staffing, procedure growth rates, capital replacement trends, and regulatory clearances.

Management Comments

• Minimally invasive care is life-enhancing care, and by combining ingenuity and intelligent technology, we expand the potential of physicians to heal without constraints.
• We envision a future of care that is less invasive and profoundly better, where diseases are identified early and treated quickly so patients can get back to what matters most.
• Our goal is to provide products to physicians who, in turn, provide patients with procedure options that are both highly effective and less invasive than others.
• We believe that robotic-assisted surgery with the da Vinci surgical system can help hospitals build value by increasing surgical revenue and reducing costs through lower complication rates and reduced lengths of patient stay.

Industry Context

StockSavvy.ai notes that Intuitive Surgical operates in a highly competitive landscape, facing established players like Johnson & Johnson and Medtronic plc in advanced energy and stapling, as well as emerging robotic-assisted surgery competitors globally. The company's strong growth in da Vinci and Ion procedures, coupled with new product launches like da Vinci 5 and AI-powered Ion software, positions it as a leader in the robotic-assisted medical procedures market. However, the decline in bariatric procedures due to the rise of weight-loss drugs highlights the dynamic nature of the healthcare industry and the need for continuous innovation and adaptation to alternative therapeutic approaches.

Comparison to Industry Standards

• Intuitive Surgical's 18% da Vinci procedure growth and 51% Ion procedure growth in 2025 demonstrate strong performance, outpacing general medical device market growth rates, which typically range in the mid-single digits.
• The company's da Vinci installed base of over 11,000 systems significantly exceeds that of competitors like Medtronic's Hugo RAS system or CMR Surgical's Versius, solidifying its dominant market position in robotic-assisted surgery.
• The introduction of the da Vinci 5 with force feedback technology and advanced digital experiences sets a new benchmark for surgical robotics, offering capabilities that competitors are still developing or have not yet integrated.
• The decline in bariatric procedures due to weight-loss drugs indicates a vulnerability to non-surgical alternatives, a trend that other medical device companies in elective procedure markets may also face.
• The company's gross profit margin of 66.0% remains strong, though the slight decrease due to tariffs and new product costs suggests ongoing pressure common across the medical device manufacturing sector.

Management Changes

Corporate Governance

Legal Proceedings

• The company is a defendant in multiple individual product liability lawsuits alleging personal injuries or death from da Vinci surgical system use, purported product defects, and inadequate training/disclosure of risks. Plaintiffs seek recovery for injuries and punitive damages.
• Surgical Instrument Service Company, Inc. (SIS) filed an antitrust complaint against the company in May 2021, alleging claims related to EndoWrist service, maintenance, and repair processes. The court ruled in Intuitive's favor on all antitrust claims in January 2025, but SIS filed a Notice of Appeal in February 2025.
• Three class action complaints were filed against the company in the Northern District of California Court alleging antitrust violations related to the service and repair of certain instruments. A consolidated amended complaint was filed, and the court granted plaintiffs' motion for class certification in March 2025. No trial date has been scheduled.
• Restore Robotics Repairs filed an antitrust complaint in September 2024 related to service and replacement of X/Xi EndoWrist instruments. The court granted Intuitive's motion to dismiss in November 2025, and Restore filed a notice of appeal in November 2025.

Related Party Transactions

• The company holds a 60% controlling financial interest in the Joint Venture (Intuitive Surgical-Fosun Medical Technology (Shanghai) Co., Ltd. and Intuitive Surgical-Fosun (HongKong) Co., Ltd.) with Shanghai Fosun Pharmaceutical (Group) Co., Ltd. (Fosun Pharma) in China. The Joint Venture manufactures and distributes da Vinci products and services in China.

Stakeholder Impact

• Shareholders: Benefit from strong revenue and procedure growth, increased operating income, and an active stock repurchase program. However, potential stock price volatility due to market fluctuations and litigation risks remains.
• Patients: Benefit from expanded access to minimally invasive care through new product innovations (da Vinci 5, Ion AI) and broader indications, aiming for better outcomes and experiences.
• Physicians and Care Teams: Gain enhanced capabilities, improved ergonomics, and comprehensive training through new systems and learning technologies, aiming to improve their experience and efficiency.
• Hospitals and Healthcare Systems: Potential for increased surgical revenue, reduced costs through lower complication rates, and optimized robotic programs, but face capital spending constraints, staffing challenges, and pricing pressures.
• Employees: Benefit from competitive compensation, benefits, and talent development programs, with a focus on inclusion and diversity. However, the company faces intense competition for qualified personnel and risks associated with knowledge transfer.
• Suppliers: Subject to supply chain disruptions, inflationary pressures, and potential insolvency risks, particularly for soleand single-sourced suppliers.

Next Steps

• Continue phased launch of da Vinci 5 surgical system in OUS markets over several quarters.
• Seek additional FDA clearances for da Vinci SP surgical system for new indications.
• Expand the da Vinci SP instrument offering over time.
• Seek additional clearances, approvals, and certifications for Ion endoluminal system in OUS markets.
• Complete the acquisition of da Vinci and Ion distribution businesses in Italy, Spain, Portugal, Malta, and San Marino in the first half of 2026.
• Continue to make substantial investments in research and development for multi-port, Ion, and SP platform initiatives, as well as digital products and services.
• Monitor and mitigate supply chain risks and disruptions, including those related to tariffs and critical materials.

Key Dates

Recommendation

Intuitive Surgical's 2025 performance demonstrates robust growth across its core surgical robotics and diagnostic platforms, driven by strong procedure adoption and successful new product launches like the da Vinci 5. The company's significant R&D investments and strategic market expansions, despite macroeconomic headwinds and competitive pressures, reinforce its leadership position. The strong cash flow and active share repurchase program further enhance shareholder value, making it an attractive long-term investment.

Keywords

Robotic-assisted surgery, Minimally invasive surgery, da Vinci surgical system, Ion endoluminal system, Medical devices, Healthcare technology, Surgical robotics, Financial results 2025, SEC 10-K, Intuitive Surgical, ISRG